110 related articles for article (PubMed ID: 9554329)
1. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity.
Grossfeld GD; Olumi AF; Connolly JA; Chew K; Gibney J; Bhargava V; Waldman FM; Carroll PR
J Urol; 1998 May; 159(5):1437-43. PubMed ID: 9554329
[TBL] [Abstract][Full Text] [Related]
2. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
[TBL] [Abstract][Full Text] [Related]
3. Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy.
Connolly JA; Presti JC; Cher ML; Chew K; Shinohara K; Carroll PR
J Urol; 1997 Aug; 158(2):515-8. PubMed ID: 9224336
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
6. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
7. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
9. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
[TBL] [Abstract][Full Text] [Related]
10. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.
Merseburger AS; Kuczyk MA; Serth J; Bokemeyer C; Young DY; Sun L; Connelly RR; McLeod DG; Mostofi FK; Srivastava SK; Stenzl A; Moul JW; Sesterhenn IA
Oncol Rep; 2003; 10(1):223-8. PubMed ID: 12469173
[TBL] [Abstract][Full Text] [Related]
11. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
Westin P; Stattin P; Damber JE; Bergh A
Am J Pathol; 1995 Jun; 146(6):1368-75. PubMed ID: 7778676
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas.
Tsai ST; Jin YT; Leung HW; Wang ST; Tsao CJ; Su IJ
Anticancer Res; 1998; 18(4B):2849-54. PubMed ID: 9713473
[TBL] [Abstract][Full Text] [Related]
13. Protein expression of p53 and Bcl-2 has a strong correlation with radiation resistance of laryngeal squamous cell carcinoma but does not predict the radiation failure before treatment.
Ogawa T; Shiga K; Tateda M; Saijo S; Suzuki T; Sasano H; Miyagi T; Kobayashi T
Oncol Rep; 2003; 10(5):1461-6. PubMed ID: 12883724
[TBL] [Abstract][Full Text] [Related]
14. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
[TBL] [Abstract][Full Text] [Related]
15. p53 protein and gene alterations in pathological stage C prostate carcinoma.
Salem CE; Tomasic NA; Elmajian DA; Esrig D; Nichols PW; Taylor CR; Skinner DG; Roy-Burman P; Lieskovsky G; Cote RJ
J Urol; 1997 Aug; 158(2):510-4. PubMed ID: 9224335
[TBL] [Abstract][Full Text] [Related]
16. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
17. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population.
Inoue T; Segawa T; Shiraishi T; Yoshida T; Toda Y; Yamada T; Kinukawa N; Kinoshita H; Kamoto T; Ogawa O
Urology; 2005 Aug; 66(2):332-7. PubMed ID: 16098362
[TBL] [Abstract][Full Text] [Related]
20. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Shimizu K; Miyakita M; Ogata Y
Anticancer Res; 2001; 21(3C):2149-53. PubMed ID: 11501839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]